ArticleFrontiers in cardiovascular medicine2026
Therapeutic efficacy of recombinant human brain natriuretic peptide in elderly chronic heart failure patients: associations with changes in PⅢNP and suPAR levels.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) added to conventional treatment in elderly patients with chronic heart failure (CHF), and to analyze its regulatory effects on fibrosis- and inflammation-related biomarkers such as procollagen type III amino-terminal propeptide (PⅢNP) and soluble urokinase-type plasminogen activator receptor (suPAR). Methods: A retrospective comparative cohort study was conducted to collect clinical data of 124 elderly CHF patients treated in our hospital from February 2023 to April 2025. According to the treatment regimens received, the patients were divided into two groups: the control group ( Results: (1) Clinical therapeutic effects: Post-treatment, the overall efficacy of the study group was significantly better than that of the control group (total effective rate: 93.55% vs. 82.26%, Conclusion: Elderly CHF patients receiving rhBNP in addition to conventional treatment showed significantly greater improvements in cardiac function, myocardial injury markers, blood gas parameters, and fibrosis- and inflammation-related biomarkers (PⅢNP, suPAR). Meanwhile, the treatment was well tolerated, with no obvious increase in adverse reactions or adverse prognosis. However, considering the limitations of the study design, these findings mainly reflect correlation rather than causation. Further validation is required through multicenter, large-sample, prospective randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.